<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f300c5a2-8b31-4603-b867-16c030f893dc"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.<br/>
      <br/>METFORMIN HYDROCHLORIDE extended-release tablets, for oral use<br/>Initial U.S. Approval: 1995<br/>
   </title>
   <effectiveTime value="20190408"/>
   <setId root="85027e6c-d35b-49eb-a234-dd71aa77aee0"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="081468959" root="1.3.6.1.4.1.519.1"/>
            <name>Viona Pharmaceuticals Inc</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="650199482" root="1.3.6.1.4.1.519.1"/>
                  <name>Cadila Healthcare Limited Zydus Tower</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="918596198" root="1.3.6.1.4.1.519.1"/>
                        <name>Cadila Healthcare Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72578-035" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72578-036" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72578-035" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72578-036" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4208f728-b6d1-4fc1-b460-abaf30556ad3"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20190408"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72578-035" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metformin Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metformin Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="500" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METFORMIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="73CJJ317SR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL BEHENATE/EICOSADIOATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-035-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190315"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-035-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190315"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077060" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190315"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE">
                              <originalText>capsule</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="19" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">63;Z</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72578-036" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metformin Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metformin Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="750" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="786Z46389E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METFORMIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9100L32L2N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METFORMIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="73CJJ317SR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL BEHENATE/EICOSADIOATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-036-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190315"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-036-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190315"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077078" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190315"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE">
                              <originalText>capsule</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="19" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Z;C;20</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="15c9ba2e-f17d-4da9-9ff8-b26d50a94049"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>BOXED WARNING</title>
               <text>
                  <paragraph ID="ID155">
                     <content styleCode="bold">WARNING: LACTIC ACIDOSIS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin  associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin  associated lactic acidosis was characterized by elevated blood lactate levels (&gt;5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally &gt;5 mcg/mL [see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)</content>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see <content styleCode="italics">Dosage and Administration (<linkHtml href="#ID15">2.3</linkHtml>),  Contraindications (<linkHtml href="#ID31">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)</content>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)</content>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID4">
                           <content styleCode="bold">WARNING: LACTIC ACIDOSIS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID5" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Postmarketing cases of      metformin-associated lactic acidosis have resulted in death, hypothermia,      hypotension, and resistant bradyarrhythmias. Symptoms included malaise,      myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory      abnormalities included elevated blood lactate levels, anion gap acidosis,      increased lactate/pyruvate ratio; and metformin plasma levels generally      &gt;5 mcg/mL. (<linkHtml href="#ID36">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Risk factors include renal      impairment, concomitant use of certain drugs, age &gt;65 years old, radiological      studies with contrast, surgery and other procedures, hypoxic states,      excessive alcohol intake, and hepatic impairment. Steps to reduce the risk      of and manage metformin associated lactic acidosis in these high risk      groups are provided in the Full Prescribing Information. (<linkHtml href="#ID36">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">If lactic acidosis is      suspected, discontinue metformin hydrochloride extended-release tablets      and institute general supportive measures in a hospital setting. Prompt      hemodialysis is recommended. (<linkHtml href="#ID36">5.1</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID7">
               <id root="b5423153-4ec6-49ec-a817-ed52f5555a65"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID8">Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</paragraph>
               </text>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID10">Metformin hydrochloride extended-release tablets are biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (<linkHtml href="#ID7">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID11">
               <id root="99dadb93-bb9c-480e-992b-023b95da8cc0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID20">
                           <content styleCode="bold">
                              <content styleCode="italics">Adult Dosage for Metformin Hydrochloride Extended-Release Tablets: </content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID21" styleCode="Disc">
                           <item>Swallow metformin hydrochloride      extended-release tablets whole and never crush, cut or chew (<linkHtml href="#ID12">2.1</linkHtml>)</item>
                           <item>Starting dose: 500 mg orally once daily with the evening meal (<linkHtml href="#ID12">2.1</linkHtml>)</item>
                           <item>Increase the dose in increments of 500 mg weekly, up to a      maximum of 2,000 mg once daily with the evening meal (<linkHtml href="#ID12">2.1</linkHtml>)</item>
                           <item>Patients receiving metformin      hydrochloride tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once      daily (<linkHtml href="#ID12">2.1</linkHtml>)</item>
                        </list>
                        <paragraph ID="ID22">
                           <content styleCode="bold">
                              <content styleCode="italics">Renal Impairment:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID23" styleCode="Disc">
                           <item>Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (<linkHtml href="#ID15">2.3</linkHtml>)<list listType="unordered" styleCode="Circle">
                                 <item>Do not use in patients with eGFR below 30 mL/minute/1.73 m<sup>2</sup>(<linkHtml href="#ID15">2.3</linkHtml>)</item>
                                 <item>Initiation is not recommended in patients with eGFR between 30 mL/minute/1.73 m<sup>2</sup>to 45 mL/minute/1.73 m<sup>2</sup>(<linkHtml href="#ID15">2.3</linkHtml>)</item>
                                 <item>Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m<sup>2</sup>(<linkHtml href="#ID15">2.3</linkHtml>)</item>
                                 <item>Discontinue if eGFR falls below 30 mL/minute/1.73 m<sup>2</sup>(<linkHtml href="#ID15">2.3</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                        <paragraph ID="ID24">
                           <content styleCode="bold">
                              <content styleCode="italics">Discontinuation for Iodinated Contrast Imaging Procedures:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID25" styleCode="Disc">
                           <item>Metformin hydrochloride extended-release tablets      may need to be discontinued at time of, or prior to, iodinated contrast      imaging procedures (<linkHtml href="#ID17">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID12">
                     <id root="62d64a56-5113-41f5-8ca1-5a0d3a33b624"/>
                     <title>2.1 Adult Dosage</title>
                     <text>
                        <paragraph ID="ID13">
                           <content styleCode="bold">
                              <content styleCode="italics">Metformin Hydrochloride Extended-Release Tablets </content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID14" styleCode="Disc">
                           <item>Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew.</item>
                           <item>The recommended starting dose of metformin hydrochloride extended-release tablets are 500 mg orally once daily with the evening meal.</item>
                           <item>Increase the dose in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg once daily with the evening meal.</item>
                           <item>If glycemic control is not achieved with metformin hydrochloride extended-release tablets 2,000 mg once daily, consider a trial of metformin hydrochloride extended-release tablets 1,000 mg twice daily. If higher doses are required, switch to metformin hydrochloride tablets at total daily doses up to 2,550 mg administered in divided daily doses, as described above.</item>
                           <item>Patients receiving metformin hydrochloride tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily.</item>
                        </list>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID15">
                     <id root="cdb613d3-87e5-4f0f-b907-438638f46cfe"/>
                     <title>2.3 Recommendations for Use in Renal Impairment</title>
                     <text>
                        <list listType="unordered" ID="ID16" styleCode="Disc">
                           <item>Assess renal function prior to initiation of      metformin hydrochloride extended-release tablets and periodically thereafter.</item>
                           <item>Metformin hydrochloride      extended-release tablets are contraindicated in patients with an estimated glomerular filtration      rate (eGFR) below 30 mL/minute/1.73      m<sup>2</sup>.</item>
                           <item>Initiation of metformin      hydrochloride extended-release tablets in patients with an      eGFR between 30 mL/minute/1.73 m<sup>2</sup>to 45 mL/minute/1.73 m<sup>2</sup>is not recommended.</item>
                           <item>In patients taking metformin hydrochloride      extended-release tablets whose      eGFR later falls below 45      mL/min/1.73 m<sup>2</sup>, assess the benefit risk of continuing therapy.</item>
                           <item>Discontinue      metformin hydrochloride extended-release tablets if the patient's eGFR      later falls below 30      mL/minute/1.73 m<sup>2</sup>
                              <content styleCode="italics">[</content>
                              <content styleCode="italics">s</content>
                              <content styleCode="italics">ee Warnings      and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)]</content> .</item>
                        </list>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID17">
                     <id root="44c694a7-a049-4f74-8c31-3fe0c929cfe6"/>
                     <title>2.4 Discontinuation for Iodinated Contrast Imaging Procedures</title>
                     <text>
                        <paragraph ID="ID18">Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 mL/min/1.73 m<sup>2</sup>and 60 mL/min/1.73 m<sup>2</sup>; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra- arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride extended-release tablets if renal function is stable.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID26">
               <id root="a640008c-68e8-438f-8e18-5f7006e36727"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID27">
                     <content styleCode="bold">
                        <content styleCode="italics">Metformin Hydrochloride Extended-release Tablets, USP</content>
                     </content>
                  </paragraph>
                  <list listType="unordered" ID="ID28" styleCode="Disc">
                     <item>Metformin Hydrochloride      Extended-release Tablets USP, 500 mg are white to off-white, capsule      shaped, uncoated tablets, debossed with "63" on one side and "Z"      on the other side.</item>
                     <item>Metformin Hydrochloride      Extended-release Tablets USP, 750 mg are white to off-white, capsule      shaped, uncoated tablets, debossed with "Z", "C" on one side      and "20" on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID30" styleCode="Disc">
                           <item>Metformin Hydrochloride Extended-Release      Tablets: 500 mg      and 750 mg (<linkHtml href="#ID26">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID31">
               <id root="203a4316-6666-43fc-913b-d1cb327d14cb"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID32">Metformin hydrochloride extended-release tablets are contraindicated in patients with:</paragraph>
                  <list listType="unordered" ID="ID33" styleCode="Disc">
                     <item>  Severe renal impairment (eGFR below 30 mL/min/1.73 m<sup>2</sup>) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)]</content> .</item>
                     <item>  Hypersensitivity to metformin.</item>
                     <item>  Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.</item>
                  </list>
               </text>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID161" styleCode="Disc">
                           <item>Severe renal impairment (eGFR below 30      mL/min/1.73 m<sup>2</sup>) (<linkHtml href="#ID31">4</linkHtml>, <linkHtml href="#ID36">5.1</linkHtml>)</item>
                           <item>Hypersensitivity to metformin (<linkHtml href="#ID31">4</linkHtml>)</item>
                           <item>Acute or chronic metabolic acidosis,      including diabetic ketoacidosis, with or without coma. (<linkHtml href="#ID31">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID35">
               <id root="da49a4dc-fab6-4736-8d5c-3be5af3408c4"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID62" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Lactic Acidosis: </content> See boxed      warning.      (<linkHtml href="#ID36">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Vitamin </content>
                              <content styleCode="italics">B<sub>12</sub>Deficiency: </content> Metformin may lower vitamin B<sub>12</sub>levels. Measure hematological parameters annually and vitamin B<sub>12</sub>at 2 to 3 year intervals      and manage      any abnormalities. (<linkHtml href="#ID55">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Hypoglycemia with Concomitant Use with      Insulin      and Insulin      Secretagogues: </content> Increased risk of hypoglycemia      when used      in combination      with insulin      and/or an insulin secretagogue. Lower dose of insulin      or insulin      secretagogue may be      required (<linkHtml href="#ID57">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID36">
                     <id root="764e23ef-accc-42e7-819f-a547284dd878"/>
                     <title>5.1 Lactic Acidosis</title>
                     <text>
                        <paragraph ID="ID37">There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metformin  associated lactic acidosis was characterized by elevated blood lactate concentrations (&gt;5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio; metformin plasma levels were generally &gt;5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.</paragraph>
                        <paragraph>If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of metformin hydrochloride extended-release tablets. In metformin hydrochloride extended-release tablets treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery.</paragraph>
                        <paragraph>Educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur, instruct them to discontinue metformin hydrochloride extended-release tablets and report these symptoms to their healthcare provider.</paragraph>
                        <paragraph>For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:</paragraph>
                        <list listType="unordered" ID="ID38" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Renal impairment</content>
                           </item>
                        </list>
                        <paragraph ID="ID39">The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment.The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient's renal function include <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID12">2.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID105">12.3</linkHtml>)]</content>:</paragraph>
                        <list listType="unordered" ID="ID40" styleCode="Disc">
                           <item>Before initiating metformin hydrochloride      extended-release tablets, obtain an      estimated glomerular filtration      rate (eGFR).</item>
                           <item>Metformin hydrochloride      extended-release tablets are contraindicated in      patients with      an eGFR less than 30 mL/min/1.73 m<sup>2</sup>
                              <content styleCode="italics">[</content>
                              <content styleCode="italics">see      Contraindications (<linkHtml href="#ID31">4</linkHtml>)].</content>
                           </item>
                           <item>Initiation of      metformin hydrochloride extended-release tablets is not recommended in patients with eGFR      between 30 mL/min/1.73 m<sup>2</sup>to      45 mL/min/1.73 m<sup>2</sup>.</item>
                           <item>Obtain an eGFR at least annually in all patients taking metformin hydrochloride      extended-release tablets. In patients at risk for the      development of renal impairment      (e.g., the elderly), renal function should be assessed      more frequently.</item>
                           <item>In patients taking metformin hydrochloride extended-release tablets whose eGFR falls      below 45 mL/min/1.73 m<sup>2</sup>, assess the benefit and risk of continuing therapy.</item>
                        </list>
                        <list listType="unordered" ID="ID41" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Drug interactions</content>
                           </item>
                        </list>
                        <paragraph ID="ID42">The concomitant use of metformin hydrochloride extended-release tablets with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance, or increase metformin accumulation. Consider more frequent monitoring of patients.</paragraph>
                        <list listType="unordered" ID="ID43" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Age 65 or greater </content>
                           </item>
                        </list>
                        <paragraph ID="ID44">The risk of metformin-associated lactic acidosis increases with the patient's age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients.</paragraph>
                        <list listType="unordered" ID="ID45" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Radiologic studies with contrast </content>
                           </item>
                        </list>
                        <paragraph ID="ID46">Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 mL/min/1.73 m<sup>2</sup>and 60 mL/min/1.73 m<sup>2</sup>; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart metformin hydrochloride extended-release tablets if renal function is stable.</paragraph>
                        <list listType="unordered" ID="ID47" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Surgery and      other procedures</content>
                           </item>
                        </list>
                        <paragraph ID="ID48">Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension, and renal impairment. Metformin hydrochloride extended-release tablets should be temporarily discontinued while patients have restricted food and fluid intake.</paragraph>
                        <list listType="unordered" ID="ID49" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Hypoxic states </content>
                           </item>
                        </list>
                        <paragraph ID="ID50">Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may cause prerenal azotemia. When such an event occurs, discontinue metformin hydrochloride extended-release tablets.</paragraph>
                        <list listType="unordered" ID="ID51" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Excessive alcohol      intake</content>
                           </item>
                        </list>
                        <paragraph ID="ID52">Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving  metformin hydrochloride extended-release tablets.</paragraph>
                        <list listType="unordered" ID="ID53" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Hepatic impairment </content>
                           </item>
                        </list>
                        <paragraph ID="ID54">Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of metformin hydrochloride extended-release tablets in patients with clinical or laboratory evidence of hepatic disease.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID55">
                     <id root="6597b172-cbc8-457c-8360-62332e0620ba"/>
                     <title>5.2 Vitamin B12 Deficiency</title>
                     <text>
                        <paragraph ID="ID56">In metformin hydrochloride tablets clinical trials of 29 week duration, a decrease to subnormal levels of previously normal serum vitamin B<sub>12</sub> levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B<sub>12</sub> absorption from the B<sub>12</sub>-intrinsic factor complex, may be associated with anemia but appears to be rapidly reversible with discontinuation of Metformin hydrochloride tablets or vitamin B<sub>12</sub> supplementation. Certain individuals (those with inadequate vitamin B<sub>12</sub> or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B<sub>12</sub> levels. Measure hematologic parameters on an annual basis and vitamin B<sub>12</sub> at 2 to 3 year intervals in patients on metformin hydrochloride extended-release tablets and manage any abnormalities <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID66">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID57">
                     <id root="b3a13992-3fef-47e9-ad69-7e11116bc8b4"/>
                     <title>5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues</title>
                     <text>
                        <paragraph ID="ID58">Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. Metformin hydrochloride extended-release tablets may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with metformin hydrochloride extended-release tablets <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID74">7</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID59">
                     <id root="ebc04ca6-2692-4fbc-8f75-a195e71b42b2"/>
                     <title>5.4 Macrovascular Outcomes</title>
                     <text>
                        <paragraph ID="ID60">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with metformin hydrochloride extended-release tablets.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID63">
               <id root="8e92cd2c-9175-4a00-bf50-1c591cfe9781"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID64">The following adverse reactions are also discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered" ID="ID65" styleCode="Disc">
                     <item>Lactic Acidosis <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)]</content>
                     </item>
                     <item>Vitamin B<sub>12</sub>Deficiency <content styleCode="italics">[see Warnings and Precautions      (<linkHtml href="#ID55">5.2</linkHtml>)]</content>
                     </item>
                     <item>Hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID57">5.3</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID73">For metformin hydrochloride extended-release tablets, the most common adverse reactions (&gt;5.0%) are diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache. (<linkHtml href="#ID66">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID66">
                     <id root="d53235d1-60bb-427d-8bb5-b651af4287c1"/>
                     <title>6.1 Clinical Studies Experience</title>
                     <text>
                        <paragraph ID="ID67">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metformin Hydrochloride Extended-Release Tablets</content>
                           </content>
                        </paragraph>
                        <paragraph>In placebo-controlled trials, 781 patients were administered metformin hydrochloride extended-release tablets. Adverse reactions reported in greater than 5% of the metformin hydrochloride extended-release tablets patients, and that were more common in metformin hydrochloride extended-release tablets- than placebo-treated patients, are listed in Table 2.</paragraph>
                        <table ID="ID68" width="624" styleCode="Noautorules">
                           <caption>  Table 2 Adverse Reactions from Clinical Trials of Metformin Hydrochloride Extended-Release Tablets Occurring &gt;5% and More Common than Placebo in Patients with Type 2 Diabetes Mellitus </caption>
                           <col width="208"/>
                           <col width="208"/>
                           <col width="208"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center">
                                    <content styleCode="bold"> Metformin Hydrochloride Extended-Release Tablets</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=781)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=195)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Diarrhea<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nausea/Vomiting<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID69">Diarrhea led to discontinuation of metformin hydrochloride extended-release tablets in 0.6% of patients. Additionally, the following adverse reactions were reported in ≥ 1.0% to ≤ 5.0% of metformin hydrochloride extended-release tablets patients and were more commonly reported with metformin hydrochloride extended-release tablets than placebo: abdominal pain, constipation, distention abdomen, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID70">
                     <id root="bac77d54-1e52-415e-b64d-e836cc71af26"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID71">The following adverse reactions have been identified during post approval use of metformin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID74">
               <id root="20f35256-fa32-4049-bbc3-cd1559e55c66"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID75">Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.</paragraph>
                  <table ID="ID76" width="0" styleCode="Noautorules">
                     <caption>  Table 3 Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets </caption>
                     <col width="110"/>
                     <col width="516"/>
                     <tbody>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Carbonic Anhydrase Inhibitors</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider more frequent monitoring of these patients.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Examples:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Topiramate, zonisamide, acetazolamide or dichlorphenamide.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Drugs that Reduce Metformin Hydrochloride Extended-Release Tablets Clearance</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis <content styleCode="italics">[see Clinical Pharmacology (12.3)].</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Consider the benefits and risks of concomitant use with metformin hydrochloride extended-release tablets.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Examples:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Ranolazine, vandetanib, dolutegravir, and cimetidine.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Alcohol</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Alcohol is known to potentiate the effect of metformin on lactate metabolism.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Warn patients against excessive alcohol intake while receiving metformin hydrochloride extended-release tablets.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Insulin Secretagogues or Insulin</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Coadministration of metformin hydrochloride extended-release tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Drugs Affecting Glycemic Control</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Clinical Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> When such drugs are administered to a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin hydrochloride extended-release tablets, observe the patient closely for hypoglycemia.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="italics">Examples:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid.<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID78" styleCode="Disc">
                           <item>  Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring (<linkHtml href="#ID74">7</linkHtml>)</item>
                           <item>  Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use (<linkHtml href="#ID74">7</linkHtml>)</item>
                           <item>  Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake (<linkHtml href="#ID74">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID79">
               <id root="3df99e37-ce52-4e58-82cb-8ebece33f071"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20190408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID95" styleCode="Disc">
                           <item>Females and Males of Reproductive Potential: Advise premenopausal females      of the potential      for an      unintended pregnancy.      (<linkHtml href="#ID84">8.3</linkHtml>)</item>
                           <item>Geriatric Use: Assess renal function      more frequently. (<linkHtml href="#ID88">8.5</linkHtml>)</item>
                           <item>Hepatic Impairment: Avoid use in      patients      with hepatic impairment.      (<linkHtml href="#ID92">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID80">
                     <id root="fe6f3d55-5cdb-4e34-bd76-c86f8a47361c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID81">
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited data with metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk <content styleCode="italics">[see Data]. </content>There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy <content styleCode="italics">[see Clinical Considerations].</content>
                        </paragraph>
                        <paragraph>No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2 times and 5 times, respectively, a 2,550 mg clinical dose, based on body surface area <content styleCode="italics">[see Data].</content>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes mellitus with an HbA1C &gt; 7 and has been reported to be as high as 20% to 25% in women with a HbA1C &gt; 10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Clinical Considerations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                        </paragraph>
                        <paragraph>Poorly-controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Data</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Published data from postmarketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Metformin hydrochloride did not adversely affect development outcomes when administered to pregnant rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 times and 5 times a 2,550 mg clinical dose based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID82">
                     <id root="af53ad1f-145d-4504-b612-0e3f0c4a6a97"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID83">
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited published studies report that metformin is present in human milk <content styleCode="italics">[see Data]. </content>However, there is insufficient information to determine the effects of metformin on the breastfed infant and no available information on the effects of metformin on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for metformin hydrochloride extended-release tablets and any potential adverse effects on the breastfed child from metformin hydrochloride extended-release tablets or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Data</content>
                        </paragraph>
                        <paragraph>Published clinical lactation studies report that metformin is present in human milk which resulted in infant doses approximately 0.11% to 1% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.13 and 1. However, the studies were not designed to definitely establish the risk of use of metformin during lactation because of small sample size and limited adverse event data collected in infants.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID84">
                     <id root="3ae3a1da-88fb-4da3-aaab-95fd63402b24"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph ID="ID85">Discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin hydrochloride extended-release tablets may result in ovulation in some anovulatory women.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID86">
                     <id root="64e44e45-fa71-496d-a665-e1c10eb60539"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID87">
                           <content styleCode="bold">
                              <content styleCode="italics">Metformin Hydrochloride Extended-Release Tablets</content>
                           </content>
                        </paragraph>
                        <paragraph>Safety and effectiveness of metformin hydrochloride extended-release tablets in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID88">
                     <id root="6b512a07-bc50-4c1b-abb9-039193e1f529"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID89">Controlled clinical studies of metformin hydrochloride extended-release tablets did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID90">
                     <id root="6ac12490-18af-433b-89a0-c6e8a2c653fb"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID91">Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Metformin hydrochloride extended-release tablets are contraindicated in severe renal impairment, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m<sup>2</sup>
                           <content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#ID15">2.3</linkHtml>), Contraindications (<linkHtml href="#ID31">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID105">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID92">
                     <id root="79985a9f-e68b-4937-8257-df3f218398ab"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID93">Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Metformin hydrochloride extended-release tablets are not recommended in patients with hepatic impairment. <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID96">
               <id root="eb28add4-6bf3-4a3f-bef6-de3f53b72167"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID97">Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)]</content>. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.</paragraph>
               </text>
               <effectiveTime value="20190408"/>
            </section>
         </component>
         <component>
            <section ID="ID98">
               <id root="f16111b4-1d8b-4c2a-ace9-7f1677c2558e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID99">Metformin hydrochloride extended-release tablets contain the antihyperglycemic agent metformin, which is a biguanide, in the form of monohydrochloride. The chemical name of metformin hydrochloride is <content styleCode="italics">N,N</content>-dimethylimidodicarbonimidic diamide hydrochloride. The structural formula is as shown below:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID101">Metformin hydrochloride, USP is a white crystalline powder with a molecular formula of C<sub>4</sub>H<sub>11</sub>N<sub>5</sub> • HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water, slightly soluble in alcohol and is practically insoluble in acetone and methylene chloride. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68.</paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets, USP contains 500 mg or 750 mg of metformin hydrochloride, USP as the active ingredient.</paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets, USP 500 mg and 750 mg contains the inactive ingredients glyceryl behenate, hypromellose, microcrystalline cellulose and povidone.</paragraph>
                  <paragraph>The methodology used for dissolution testing is USP Test 8 for metformin hydrochloride extended-release tablets, USP.</paragraph>
               </text>
               <effectiveTime value="20190408"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="f300c5a2-8b31-4603-b867-16c030f893dc-figure-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID102">
               <id root="6a9a9d94-1ef2-45d9-b8b9-5a8cdf62a2d6"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20190408"/>
               <component>
                  <section ID="ID103">
                     <id root="804edf98-94bf-49f6-8e16-db607b39ce41"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID104">Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID105">
                     <id root="21944d47-a0e2-46fc-b220-550f2a11675d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID106">
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption</content>
                           </content>
                        </paragraph>
                        <paragraph>The absolute bioavailability of metformin hydrochloride tablets, 500 mg given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin hydrochloride tablets 500 mg to 1,500 mg and 850 mg to 2,550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. At usual clinical doses and dosing schedules of metformin hydrochloride tablets, steady state plasma concentrations of metformin are reached within 24 hours to 48 hours and are generally &lt;1 μg/mL.</paragraph>
                        <paragraph>Following a single oral dose of metformin hydrochloride extended-release tablets, C<sub>max</sub> is achieved with a median value of 7 hours and a range of 4 hours to 8 hours. Peak plasma levels are approximately 20% lower compared to the same dose of metformin hydrochloride tablets, however, the extent of absorption (as measured by AUC) is comparable to metformin hydrochloride tablets.</paragraph>
                        <paragraph>At steady state, the AUC and C<sub>max</sub> are less than dose proportional for metformin hydrochloride extended-release tablets within the range of 500 to 2,000 mg administered once daily. Peak plasma levels are approximately 0.6 mcg/mL, 1.1 mcg/mL, 1.4 mcg/mL and 1.8 mcg/mL for 500 mg, 1,000 mg, 1,500 mg and 2,000 mg once-daily doses, respectively. The extent of metformin absorption (as measured by AUC) from metformin hydrochloride extended-release tablets at a 2,000 mg once-daily dose is similar to the same total daily dose administered as metformin hydrochloride tablets 1,000 mg twice daily. After repeated administration of metformin hydrochloride extended-release tablets, metformin did not accumulate in plasma.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of food: </content>
                        </paragraph>
                        <paragraph>Food decreases the extent of absorption and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (C<sub>max</sub>), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (T<sub>max</sub>) following administration of a single 850 mg tablet of metformin hydrochloride tablets with food, compared to the same tablet strength administered fasting.</paragraph>
                        <paragraph>Although the extent of metformin absorption (as measured by AUC) from the metformin hydrochloride extended-release tablets tablet increased by approximately 50% when given with food, there was no effect of food on C<sub>max</sub> and T<sub>max</sub> of metformin. Both high and low fat meals had the same effect on the pharmacokinetics of metformin hydrochloride extended-release tablets.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution</content>
                           </content>
                        </paragraph>
                        <paragraph>The apparent volume of distribution (V/F) of metformin following single oral doses of metformin hydrochloride tablets 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Elimination</content>
                           </content>
                        </paragraph>
                        <paragraph>Renal clearance (see Table 4) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Renal Impairment</content>
                           </content>
                        </paragraph>
                        <paragraph>In patients with decreased renal function the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased (see Table 3) <content styleCode="italics">[See Dosage and Administration (2.3), Contraindications (4), Warnings and Precautions (5.1) and Use in Specific Populations (8.6)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hepatic </content>Impairment</content>
                        </paragraph>
                        <paragraph>No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment <content styleCode="italics">[See Warnings and Precautions (5.1) and Use in Specific Populations (8.7)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Geriatrics</content>
                           </content>
                        </paragraph>
                        <paragraph>Limited data from controlled pharmacokinetic studies of metformin hydrochloride tablets in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and C<sub>max</sub> is increased, compared to healthy young subjects. It appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 4). <content styleCode="italics">[See Warnings and Precautions (5.1) and Use in Specific Populations (8.5)]</content>.</paragraph>
                        <table ID="ID107" width="624" styleCode="Noautorules">
                           <caption>  Table 4 Select Mean (±S.D.) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of Metformin Hydrochloride Tablets </caption>
                           <col width="318"/>
                           <col width="102"/>
                           <col width="90"/>
                           <col width="114"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> All doses given fasting except the first 18 doses of the multiple dose studies</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup> Peak plasma concentration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup> Time to peak plasma concentration</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>d</sup> Combined results (average means) of five studies: mean age 32 years (range 23 years to59 years)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>e</sup> Kinetic study done following dose 19, given fasting</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>f</sup> Elderly subjects, mean age 71 years (range 65 years to 81 years)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>g</sup> CL<sub>cr</sub>= creatinine clearance normalized to body surface area of 1.73 m<sup>2</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Subject Groups: Metformin Hydrochloride Tablets dose<sup>a</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (number of subjects)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> C</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                       <sup>b</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (mcg/mL)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> T</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                       <sup>c</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (hrs)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Renal Clearance</content>
                                    <br/>
                                    <content styleCode="bold"> (mL/min)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Healthy, nondiabetic adults:</content>
                                    <br/> 500 mg single dose (24)<br/> 850 mg single dose (74)<sup>d</sup>
                                    <br/> 850 mg three times daily for 19 doses<sup>e</sup> (9)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.03 (±0.33)<br/> 1.60 (±0.38)<br/> 2.01 (±0.42)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.75 (±0.81)<br/> 2.64 (±0.82)<br/> 1.79 (±0.94)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 600 (±132)<br/> 552 (±139)<br/> 642 (±173)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Adults with type 2 diabetes mellitus:</content>
                                    <br/> 850 mg single dose (23)<br/> 850 mg three times daily for 19 doses<sup>e</sup> (9)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.48 (±0.5)<br/> 1.90 (±0.62)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.32 (±1.08)<br/> 2.01 (±1.22)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 491 (±138)<br/> 550 (±160)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Elderly</content>
                                    <sup>f</sup>
                                    <content styleCode="bold"> , healthy nondiabetic adults:</content>
                                    <br/> 850 mg single dose (12)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.45 (±0.70)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.71 (±1.05)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 412 (±98)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Renal-impaired adults:</content>
                                    <br/>
                                    <content styleCode="bold"> 850 mg single dose</content>
                                    <br/>
                                    <content styleCode="bold"> Mild </content> (CL<sub>cr</sub>
                                    <sup>g</sup>61 mL/min  to 90 mL/min) (5)<br/>
                                    <content styleCode="bold"> Moderate </content> (CL<sub>cr</sub> 31 mL/min to 60 mL/min) (4)<br/>
                                    <content styleCode="bold"> Severe </content> (CL<sub>cr </sub>10 mL/min to 30 mL/min) (6)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.86 (±0.52)<br/> 4.12 (±1.83)<br/> 3.93 (±0.92)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.20 (±0.45)<br/> 3.75 (±0.50)<br/> 4.01 (±1.10)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 384 (±122)<br/> 108 (±57)<br/> 130 (±90)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID108">
                           <content styleCode="bold">
                              <content styleCode="italics">Pediatrics</content>
                           </content>
                        </paragraph>
                        <paragraph>After administration of a single oral metformin hydrochloride tablets 500 mg tablet with food, geometric mean metformin C<sub>max</sub> and AUC differed less than 5% between pediatric type 2 diabetic patients (12 years to 16 years of age) and gender- and weight-matched healthy adults (20 years to 45 years of age), all with normal renal function.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gender</content>
                           </content>
                        </paragraph>
                        <paragraph>Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes mellitus when analyzed according to gender (males=19, females=16).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Race</content>
                           </content>
                        </paragraph>
                        <paragraph>No studies of metformin pharmacokinetic parameters according to race have been performed.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">In Vivo</content> <content styleCode="italics">Assessment of Drug Interactions</content>
                           </content>
                        </paragraph>
                        <table ID="ID109" width="100%" styleCode="Noautorules">
                           <caption>  Table 5 Effect of Coadministered Drug on Plasma Metformin Systemic Exposure </caption>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>*</sup> All metformin and coadministered drugs were given as single doses</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>†</sup> AUC = AUC(INF)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>‡</sup> Ratio of arithmetic means</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>§</sup> At steady state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC<sub>0 to 12h</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule Botrule" align="center">
                                    <content styleCode="bold"> Coadministered</content>
                                    <br/>
                                    <content styleCode="bold"> Drug</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of Coadministered</content>
                                    <br/>
                                    <content styleCode="bold"> Drug<sup>*</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of</content>
                                    <br/>
                                    <content styleCode="bold"> Metformin<sup>*</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Geometric Mean Ratio</content>
                                    <br/>
                                    <content styleCode="bold"> (ratio with/without coadministered drug) No Effect = 1.00</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AUC</content>
                                    <sup>†</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> C</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> No dosing adjustments required for the following:</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Glyburide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.91<sup>‡</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.93<sup>‡</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Furosemide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.09<sup>‡</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.22<sup>‡</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nifedipine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.16<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.21<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Propranolol<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.90<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.94<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ibuprofen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.05<sup>‡</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.07<sup>‡</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination </content> [See <content styleCode="italics">W</content>
                                    <content styleCode="italics">arnings and Precautions (5.9) </content> and <content styleCode="italics">Drug Interactions (7.2).</content> ]<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cimetidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.40<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.61<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Carbonic anhydrase inhibitors may cause metabolic acidosis </content> [See <content styleCode="italics">Warnings and Precautions (5.1) </content> and <content styleCode="italics">Drug Interactions (7.1).</content> ]<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Topiramate<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 100 mg<sup>§</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 500 mg<sup>§</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> metformin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.25<sup>§</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.17<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID110" width="634" styleCode="Noautorules">
                           <caption>  Table 6 Effect of Metformin on Coadministered Drug Systemic Exposure </caption>
                           <col width="120"/>
                           <col width="163"/>
                           <col width="100"/>
                           <col width="94"/>
                           <col width="88"/>
                           <col width="69"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>*</sup> All metformin and coadministered drugs were given as single doses</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>†</sup> AUC = AUC(INF) unless otherwise noted</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>‡</sup> Ratio of arithmetic means, p-value of difference &lt;0.05</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>§</sup> AUC(0hr to 24 hr) reported</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>¶</sup> Ratio of arithmetic means</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule Botrule" align="center">
                                    <content styleCode="bold"> Coadministered</content>
                                    <br/>
                                    <content styleCode="bold"> Drug</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of</content>
                                    <br/>
                                    <content styleCode="bold"> Coadministered Drug</content>
                                    <sup>*</sup>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose of</content>
                                    <br/>
                                    <content styleCode="bold"> Metformin</content>
                                    <sup>*</sup>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Geometric Mean Ratio (ratio with/without metformin) </content>
                                    <br/>
                                    <content styleCode="bold"> No Effect = 1</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AUC</content>
                                    <sup>†</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> C<sub>max</sub>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> No dosing adjustments required for the following:</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Glyburide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> glyburide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.78<sup>‡</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.63<sup>‡</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Furosemide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> furosemide<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.87<sup>‡</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.69<sup>‡</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nifedipine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> nifedipine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.10<sup>§</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.08<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Propranolol<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 40 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> propranolol<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<sup>§</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.02<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ibuprofen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> ibuprofen<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.97<sup>¶</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<sup>¶</sup>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cimetidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 400 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 850 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> cimetidine<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.95<sup>§</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.01<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID111">
               <id root="7d3fb4e5-46e7-4a27-bb7f-4705f00fd01f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20190408"/>
               <component>
                  <section ID="ID112">
                     <id root="164692cd-19ed-4801-81f9-867ca11b5056"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID113">Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1,500 mg/kg/day, respectively. These doses are both approximately 3 times the maximum recommended human daily dose of 2,550 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.</paragraph>
                        <paragraph>There was no evidence of a mutagenic potential of metformin in the following <content styleCode="italics">in vitro </content>tests: Ames test (<content styleCode="italics">S. typhimurium</content>), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the <content styleCode="italics">in vivo </content>mouse micronucleus test were also negative.</paragraph>
                        <paragraph>Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 2 times the maximum recommended human daily dose of 2,550 mg based on body surface area comparisons.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID114">
               <id root="ef5cf027-87f7-41fc-98e0-ea3708b9b7bb"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20190408"/>
               <component>
                  <section ID="ID115">
                     <id root="af9a12d7-2062-4536-b97d-b25219046596"/>
                     <title>14.2 Metformin Hydrochloride Extended-Release Tablets</title>
                     <text>
                        <paragraph ID="ID116">A 24 week, double-blind, placebo-controlled study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal, was conducted in patients with type 2 diabetes mellitus who had failed to achieve glycemic control with diet and exercise. Patients entering the study had a mean baseline HbA1c of 8.0% and a mean baseline FPG of 176 mg/dL. The treatment dose was increased to 1,500 mg once daily if at Week 12 HbA1c was ≥7.0% but &lt;8.0% (patients with HbA1c ≥8.0% were discontinued from the study). At the final visit (24 week), mean HbA1c had increased 0.2% from baseline in placebo patients and decreased 0.6% with metformin hydrochloride extended-release tablets.</paragraph>
                        <paragraph>A 16 week, double-blind, placebo-controlled, dose-response study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal or twice daily with meals, was conducted in patients with type 2 diabetes mellitus who had failed to achieve glycemic control with diet and exercise. The results are shown in Table 10.</paragraph>
                        <table ID="ID117" width="633" styleCode="Noautorules">
                           <caption>  Table 10 Mean Changes from Baseline<sup>*</sup> in HbA1c and Fasting Plasma Glucose at Week 16 Comparing Metformin Hydrochloride Extended-Release Tablets vs. Placebo in Patients with Type 2 Diabetes Mellitus </caption>
                           <col width="199"/>
                           <col width="72"/>
                           <col width="78"/>
                           <col width="72"/>
                           <col width="72"/>
                           <col width="72"/>
                           <col width="68"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup> All comparisons versus Placebo</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td colspan="5" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Metformin Hydrochloride Extended-Release Tablets</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 500 mg Once Daily</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1,000 mg Once Daily</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1,500 mg Once Daily</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 2,000 mg Once Daily</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1,000 mg Twice Daily</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Hemoglobin A1c (%)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=115)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=115)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=111)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=125)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=112)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=111)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Baseline<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8.4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Change at FINAL VISIT<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –0.4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –0.6<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –0.9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –0.8<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –1.1<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> p-value<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> FPG (mg/dL)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=126)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=118)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=120)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=132)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=122)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=113)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Baseline<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 182.7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 183.7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 178.9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 181.0<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 181.6<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 179.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Change at FINAL VISIT<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –15.2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –19.3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –28.5<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –29.9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –33.6<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> p-value<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> &lt;0.001<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> –<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID118">Mean baseline body weight was 193 lbs, 192 lbs, 188 lbs, 196 lbs, 193 lbs and 194 lbs in the metformin hydrochloride extended-release tablets 500 mg , 1,000 mg, 1,500 mg, and 2,000 mg once daily, 1,000 mg twice daily and placebo arms, respectively. Mean change in body weight from baseline to week 16 was -1.3 lbs, -1.3 lbs, -0.7 lbs, -1.5 lbs, -2.2 lbs and -1.8 lbs, respectively.</paragraph>
                        <paragraph>A 24 week, double-blind, randomized study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal, and metformin hydrochloride tablets, taken twice daily (with breakfast and evening meal), was conducted in patients with type 2 diabetes mellitus who had been treated with metformin hydrochloride tablets 500 mg twice daily for at least 8 weeks prior to study entry. The results are shown in Table 11.</paragraph>
                        <table ID="ID119" width="623" styleCode="Noautorules">
                           <caption>  Table 11 Mean Changes from Baseline<sup>*</sup> in HbA1c and Fasting Plasma Glucose at Week 24 Comparing Metformin Hydrochloride Extended-Release Tablets vs. Metformin Hydrochloride Tablets in Patients with Type 2 Diabetes Mellitus </caption>
                           <col width="187"/>
                           <col width="143"/>
                           <col width="142"/>
                           <col width="151"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>*a</sup> n=68</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Metformin Hydrochloride Tablets </content>
                                    <br/>
                                    <content styleCode="bold"> 500 mg</content>
                                    <br/>
                                    <content styleCode="bold"> Twice Daily</content>
                                    <br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Metformin Hydrochloride Extended-Release Tablets</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1,000 mg</content>
                                    <br/>
                                    <content styleCode="bold"> Once Daily</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1,500 mg</content>
                                    <br/>
                                    <content styleCode="bold"> Once Daily</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Hemoglobin A1c (%)</content>
                                    <br/> Baseline<br/> Change at FINAL VISIT (95% CI)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=67)</content>
                                    <br/> 7.06<br/> 0.14<sup>a</sup>
                                    <br/> (–0.04, 0.31)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=72)</content>
                                    <br/> 6.99<br/> 0.27<br/>  (0.11, 0.43)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=66)</content>
                                    <br/> 7.02<br/> 0.13 <br/> (–0.02, 0.28)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> FPG (mg/dL)</content>
                                    <br/> Baseline<br/> Change at FINAL VISIT (95% CI)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=69)</content>
                                    <br/> 127.2<br/> 14.0 <br/> (7.0, 21.0)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=72)</content>
                                    <br/> 131.0<br/> 11.5 <br/> (4.4, 18.6)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> (n=70)</content>
                                    <br/> 131.4<br/> 7.6 <br/> (1.0, 14.2)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID120">Mean baseline body weight was 210 lbs, 203 lbs and 193 lbs in the metformin hydrochloride tablets 500 mg twice daily, and metformin hydrochloride extended-release tablets 1,000 mg and 1,500 mg once daily arms, respectively. Mean change in body weight from baseline to week 24 was 0.9 lbs, 1.1 lbs and 0.9 lbs, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID121">
               <id root="1f2b0d35-be7c-47b5-89c4-d5c92f80fd3c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20190408"/>
               <component>
                  <section ID="ID122">
                     <id root="306e79dd-16d4-4b8b-a418-1efdf640c869"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph ID="ID123">
                           <content styleCode="bold">
                              <content styleCode="italics">Metformin Hydrochloride Extended-release Tablets, USP</content>
                           </content>
                        </paragraph>
                        <paragraph>Metformin Hydrochloride Extended-release Tablets USP, 500 mg are white to off-white, capsule shaped, uncoated tablets, debossed with "63" on one side and "Z" on the other side and are supplied as follows.</paragraph>
                        <paragraph>NDC 72578-035-01 in bottles of 100 tablets </paragraph>
                        <paragraph>NDC 72578-035-05 in bottles of 500 tablets </paragraph>
                        <paragraph>Metformin Hydrochloride Extended-release Tablets USP, 750 mg are white to off-white, capsule shaped, uncoated tablets, debossed with "Z", "C" on one side and "20" on the other side and are supplied as follows.</paragraph>
                        <paragraph>NDC 72578-036-01 in bottles of 100 tablets </paragraph>
                        <paragraph>NDC 72578-036-05 in bottles of 500 tablets</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID124">
                     <id root="909f0328-117f-4d48-9c37-d1f0c78b06d9"/>
                     <title>16.2 Storage</title>
                     <text>
                        <paragraph ID="ID125">Store at 20° to 25°C (68°to 77°F) [See USP Controlled Room Temperature].</paragraph>
                        <paragraph>Dispense in light-resistant containers.</paragraph>
                     </text>
                     <effectiveTime value="20190408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID126">
               <id root="9aa64e2c-3cbd-4a2a-a51e-0f73e940d07a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID127">Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lactic Acidosis</content>
                  </paragraph>
                  <paragraph>Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development. Advise patients to discontinue metformin hydrochloride extended-release tablets immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur. Counsel patients against excessive alcohol intake and inform patients about importance of regular testing of renal function while receiving metformin hydrochloride extended-release tablets. Instruct patients to inform their doctor that they are taking metformin hydrochloride extended-release tablets prior to any surgical or radiological procedure, as temporary discontinuation may be required <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID36">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hypoglycemia</content>
                  </paragraph>
                  <paragraph>Inform patients that hypoglycemia may occur when metformin hydrochloride extended-release tablets are coadministered with oral sulfonylureas and insulin. Explain to patients receiving concomitant therapy the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID57">5.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Vitamin </content>
                     <content styleCode="bold">B<sub>12</sub> Deficiency</content>
                  </paragraph>
                  <paragraph>Inform patients about importance of regular hematological parameters while receiving metformin hydrochloride extended-release tablets<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID55">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Females of Reproductive Age</content>
                  </paragraph>
                  <paragraph>Inform females that treatment with metformin hydrochloride extended-release tablets may result in ovulation in some premenopausal anovulatory women which may lead to unintended pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID84">8.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metformin hydrochloride extended-release tablets Administration Information</content>
                  </paragraph>
                  <paragraph>Inform patients that metformin hydrochloride extended-release tablets must be swallowed whole and not crushed, cut, or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet.</paragraph>
               </text>
               <effectiveTime value="20190408"/>
            </section>
         </component>
         <component>
            <section ID="ID128">
               <id root="65020d69-5e67-4aaf-b904-5cf32f6a29e2"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID129">Manufactured by:</paragraph>
                  <paragraph>Cadila Healthcare Ltd.</paragraph>
                  <paragraph>Ahmedabad, India</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>Viona Pharmaceuticals Inc. </paragraph>
                  <paragraph>Cranford, NJ 07016</paragraph>
                  <paragraph>Rev.: 03/19</paragraph>
               </text>
               <effectiveTime value="20190408"/>
            </section>
         </component>
         <component>
            <section ID="ID162">
               <id root="f81e77f1-d6e6-4088-a51f-b107862cca35"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <paragraph ID="ID163">
                     <content styleCode="bold">Metformin Hydrochloride (met for' min hye'' droe klor' ide) Extended-release Tablets, USP</content>
                  </paragraph>
                  <paragraph>Read the Patient Information that comes with metformin hydrochloride extended-release tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Serious side effects can happen in people taking metformin hydrochloride extended-release tablets, including:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lactic Acidosis. </content>Metformin hydrochloride, the medicine in metformin hydrochloride extended-release tablets, can cause a rare, but serious, side effect called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in a hospital.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Stop taking metformin hydrochloride extended-release tablets and call your healthcare provider right away if you get any of the following symptoms of lactic acidosis:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID164" styleCode="Disc">
                     <item>feel very      weak and tired</item>
                     <item>have unusual      (not normal) muscle pain</item>
                     <item>have trouble      breathing</item>
                     <item>have unusual      sleepiness      or sleep longer than usual</item>
                     <item>have unexplained stomach or      intestinal      problems      with nausea and      vomiting, or diarrhea</item>
                     <item>feel      cold, especially in your      arms and      legs</item>
                     <item>feel      dizzy or      lightheaded</item>
                     <item>have a slow or      irregular heartbeat</item>
                  </list>
                  <paragraph ID="ID165">
                     <content styleCode="bold">You have a higher chance of getting lactic acidosis if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID166" styleCode="Disc">
                     <item>have kidney problems. People whose      kidneys are not      working properly should not take metformin hydrochloride extended-release tablets.</item>
                     <item>have liver      problems.</item>
                     <item>have congestive heart failure that requires treatment with      medicines.</item>
                     <item>drink a      lot of      alcohol      (very often or short-term "binge" drinking).</item>
                     <item>get dehydrated      (lose a large      amount of body fluids).      This can      happen if you are sick with a fever,      vomiting, or diarrhea. Dehydration      can also happen when      you sweat a lot with activity      or exercise      and do      not drink      enough fluids.</item>
                     <item>have certain      x-ray tests with injectable      dyes or contrast agents.</item>
                     <item>have surgery.</item>
                     <item>have a heart attack,      severe infection,      or stroke.</item>
                     <item>are 80 years of age or older and have      not had your kidney function      tested.</item>
                  </list>
                  <paragraph ID="ID167">
                     <content styleCode="bold">What are metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID168" styleCode="Disc">
                     <item>Metformin hydrochloride extended-release tablets are prescription      medicines      that contain      metformin hydrochloride.      Metformin      hydrochloride extended-release tablets are used with      diet and exercise      to help control high blood sugar (hyperglycemia)      in adults with type      2 diabetes.</item>
                     <item>Metformin      hydrochloride extended-release tablets are not      for people      with type 1      diabetes.</item>
                     <item>Metformin      hydrochloride extended-release tablets are not for      people with diabetic      ketoacidosis (increased ketones      in your blood or      urine).</item>
                  </list>
                  <paragraph ID="ID169">Metformin hydrochloride extended-release tablets have the same active ingredient. However, metformin hydrochloride extended-release tablets works longer in your body. Both of these medicines help control your blood sugar in a number of ways. These include helping your body respond better to the insulin it makes naturally, decreasing the amount of sugar your liver makes, and decreasing the amount of sugar your intestines absorb. Metformin hydrochloride extended-release tablets do not cause your body to make more insulin.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Some conditions increase your chance of getting lactic acidosis, or cause other problems if you take either of these medicines. Most of the conditions listed below can increase your chance of getting lactic acidosis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take metformin hydrochloride extended-release tablets if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID170" styleCode="Disc">
                     <item>have kidney problems</item>
                     <item>are allergic to the      metformin hydrochloride in metformin hydrochloride extended-release tablets or any of the      ingredients      in metformin      hydrochloride extended-release tablets. See the end of this leaflet for a complete list of ingredients in metformin hydrochloride      extended-release tablets.</item>
                     <item>are going to get an injection of dye or contrast agents for an x-ray      procedure      or if you are going to have      surgery and not      able to eat      or drink      much. In these situations, metformin hydrochloride extended-release tablets will need to be stopped      for a short time. Talk to      your healthcare provider      about when you should stop      metformin      hydrochloride extended-release tablets and when      you should start metformin hydrochloride      extended-release tablets again. See      "<content styleCode="bold">What      is the      most important      information I      should know      about metformin      hydrochloride extended-release tablets?</content> "</item>
                  </list>
                  <paragraph ID="ID171">
                     <content styleCode="bold">What should I tell my healthcare provider before taking metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Before taking metformin hydrochloride extended-release tablets, tell your healthcare provider if you:</paragraph>
                  <list listType="unordered" ID="ID172" styleCode="Disc">
                     <item>have type 1 diabetes. Metformin hydrochloride      extended-release tablets should not      be used to treat people with type 1      diabetes.</item>
                     <item>have a history      or risk      for diabetic ketoacidosis      (high levels of certain      acids, known      as ketones,      in the blood or      urine).      Metformin      hydrochloride extended-release tablets should not be used for      the treatment of diabetic      ketoacidosis.</item>
                     <item>have kidney problems.</item>
                     <item>have liver      problems.</item>
                     <item>have heart      problems,      including congestive      heart failure.</item>
                     <item>are older      than 80 years. If you are over 80      years old you      should not      take metformin      hydrochloride extended-release tablets unless your kidneys have been      checked and they are normal.</item>
                     <item>drink alcohol      very often,      or drink      a lot      of alcohol in short-term      "binge" drinking.</item>
                     <item>are taking insulin.</item>
                     <item>have any other      medical      conditions.</item>
                     <item>are pregnant or      plan to      become      pregnant.      It is not known if metformin hydrochloride extended-release tablets will      harm your unborn baby. If you are      pregnant, talk with      your healthcare provider      about the      best way      to control      your blood sugar while you      are pregnant.</item>
                     <item>are breast-feeding or plan to      breast-feed.      It is not      known if      metformin      hydrochloride passes into your breast milk. Talk with your      healthcare provider about the best way to feed your      baby while you      take metformin hydrochloride extended-release tablets.</item>
                  </list>
                  <paragraph ID="ID173">
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>including prescription and nonprescription medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <list listType="unordered" ID="ID174" styleCode="Disc">
                     <item>Metformin hydrochloride      extended-release tablets may affect the      way other      medicines      work, and other medicines      may affect      how metformin hydrochloride extended-release tablets works.</item>
                  </list>
                  <paragraph ID="ID175">
                     <content styleCode="bold">Can metformin hydrochloride extended-release tablets be used in children?</content>
                  </paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets have not been studied in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID176" styleCode="Disc">
                     <item>Take metformin hydrochloride      extended-release tablets exactly as your healthcare      provider      tells you.</item>
                     <item>Metformin hydrochloride      extended-release tablets should be      taken with meals to      help lessen an upset stomach side effect.</item>
                     <item>Swallow metformin hydrochloride extended-release      tablets whole. Do      not crush, cut,      or chew metformin      hydrochloride extended-release tablets.</item>
                     <item>You may sometimes pass      a soft mass in your stools      (bowel movement) that      looks like metformin      hydrochloride extended-release tablets.      This is not      harmful      and will not      affect the way      metformin hydrochloride extended-release tablets works      to control      your diabetes.</item>
                     <item>When your body is under some types of stress, such      as fever, trauma (such as a car accident),      infection, or surgery, the      amount of diabetes medicine      that you need may change. Tell your healthcare      provider right away      if you have any of these problems.</item>
                     <item>Your      healthcare provider      should do      blood tests to      check how      well your      kidneys      are working before      and during      your treatment with metformin hydrochloride      extended-release tablets.</item>
                     <item>Your      healthcare provider      will check your diabetes      with regular blood tests, including your      blood sugar levels      and your      hemoglobin A1C.</item>
                     <item>Follow your healthcare provider's instructions for treating      blood sugar that is too low (hypoglycemia). Talk to your healthcare provider      if low blood sugar is a problem for you.      See "<content styleCode="bold">What are the possible      side effects      of metformin      hydrochloride extended-release tablets?</content> "</item>
                     <item>Check your      blood sugar as your healthcare provider tells you      to.</item>
                     <item>Stay on your prescribed      diet and exercise      program while      taking metformin      hydrochloride extended-release tablets.</item>
                     <item>If you      miss a dose      of metformin hydrochloride      extended-release tablets, take your next dose as      prescribed      unless your healthcare provider tells you differently.      Do not take      an extra dose      the next      day.</item>
                     <item>If you take      too much      metformin hydrochloride extended-release      tablets, call      your healthcare      provider, local      Poison Control Center, or go to the nearest hospital emergency room right away.</item>
                  </list>
                  <paragraph ID="ID177">
                     <content styleCode="bold">What should I avoid while taking metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Do not drink a lot of alcoholic drinks while taking metformin hydrochloride extended-release tablets. This means you should not binge drink for short periods, and you should not drink a lot of alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the side effects of metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID178" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Lactic acidosis. Metformin, the active ingredient in metformin hydrochloride      extended-release tablets, can cause a rare but serious condition called lactic acidosis (a buildup of      an acid in the      blood) that      can cause death. Lactic acidosis is a medical emergency and must      be treated in the      hospital.</content>
                     </item>
                  </list>
                  <paragraph ID="ID179">Call your doctor right away if you have any of the following symptoms, which could be signs of lactic acidosis:</paragraph>
                  <list listType="unordered" ID="ID180" styleCode="Disc">
                     <item>you feel cold      in your      hands or feet</item>
                     <item>you feel dizzy or lightheaded</item>
                     <item>you have a slow or      irregular      heartbeat</item>
                     <item>you feel very      weak or tired</item>
                     <item>you have trouble      breathing</item>
                     <item>you feel sleepy      or drowsy</item>
                     <item>you have stomach pains,      nausea or vomiting</item>
                  </list>
                  <paragraph ID="ID181">Most people who have had lactic acidosis with metformin have other things that, combined with the metformin, led to the lactic acidosis. Tell your doctor if you have any of the following, because you have a higher chance for getting lactic acidosis with metformin hydrochloride extended-release tablets if you:</paragraph>
                  <list listType="unordered" ID="ID182" styleCode="Disc">
                     <item>have severe kidney problems, or      your kidneys      are affected      by certain x-ray tests that use injectable dye</item>
                     <item>have liver problems</item>
                     <item>drink alcohol very often, or drink      a lot of alcohol      in short-term "binge" drinking</item>
                     <item>get dehydrated (lose      a large amount of body      fluids).      This can      happen if you      are sick      with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot      with activity or      exercise      and do not drink enough fluids</item>
                     <item>have surgery</item>
                     <item>have a heart      attack, severe infection, or stroke</item>
                  </list>
                  <paragraph ID="ID183">Common side effects of metformin hydrochloride extended-release tablets include diarrhea, nausea, and upset stomach. These side effects generally go away after you take the medicine for a while. Taking your medicine with meals can help reduce these side effects. Tell your doctor if the side effects bother you a lot, last for more than a few weeks, come back after they've gone away, or start later in therapy. You may need a lower dose or need to stop taking the medicine for a short period or for good.</paragraph>
                  <paragraph>About 3 out of every 100 people who take metformin hydrochloride extended-release tablets have an unpleasant metallic taste when they start taking the medicine. It lasts for a short time.</paragraph>
                  <paragraph>Metformin hydrochloride extended-release tablets rarely cause hypoglycemia (low blood sugar) by themselves. However, hypoglycemia can happen if you do not eat enough, if you drink alcohol, or if you take other medicines to lower blood sugar.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Store metformin hydrochloride extended-release tablets at 20° to 25°C (68° to 77°F).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep metformin hydrochloride extended-release tablets and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the use of metformin hydrochloride extended-release tablets</content>
                  </paragraph>
                  <paragraph>If you have questions or problems, talk with your doctor or other healthcare provider. You can ask your doctor or pharmacist for the information about metformin hydrochloride extended-release tablets that is written for healthcare professionals. Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use metformin hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not share your medicine with other people.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients of metformin hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Active ingredients of metformin hydrochloride extended-release tablets: metformin hydrochloride, USP.</paragraph>
                  <paragraph>Inactive ingredients in each tablet of metformin hydrochloride extended-release tablets 500 mg and 750 mg: glyceryl behenate, hypromellose, microcrystalline cellulose and povidone.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is type 2 diabetes?</content>
                  </paragraph>
                  <paragraph>Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems. </paragraph>
                  <paragraph>The main goal of treating diabetes is to lower your blood sugar to a normal level. High blood sugar can be lowered by diet and exercise, and by certain medicines when necessary.</paragraph>
                  <paragraph>Talk to your healthcare provider about how to prevent, recognize, and take care of low blood sugar (hypoglycemia), high blood sugar (hyperglycemia), and problems you have because of your diabetes.</paragraph>
                  <paragraph>Other brands listed are the trademarks of their respective owners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20190408"/>
            </section>
         </component>
         <component>
            <section ID="ID152">
               <id root="4afab51a-2a5b-4189-868f-550a5f427523"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID153">Manufactured by:</paragraph>
                  <paragraph>Cadila Healthcare Ltd.</paragraph>
                  <paragraph>Ahmedabad, India</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>Viona Pharmaceuticals Inc. </paragraph>
                  <paragraph>Cranford, NJ 07016</paragraph>
                  <paragraph>Rev.: 03/19</paragraph>
               </text>
               <effectiveTime value="20190408"/>
            </section>
         </component>
         <component>
            <section ID="ID154">
               <id root="f7df6de5-4fbd-450c-90d8-d65de8788020"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID156">Metformin Hydrochloride Extended-release Tablets USP, 500 mg</paragraph>
                  <paragraph>NDC 72578-035-01</paragraph>
                  <paragraph>100 tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID158">Metformin Hydrochloride Extended-release Tablets USP, 750 mg</paragraph>
                  <paragraph>NDC 72578-036-01</paragraph>
                  <paragraph>100 tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20190408"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Metformin HCl ER Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="f300c5a2-8b31-4603-b867-16c030f893dc-figure-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Metformin HCl ER Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="f300c5a2-8b31-4603-b867-16c030f893dc-figure-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>